kommer på TV og alle aviser globalt innen kort tid dager.
Bergen, Norway 21 April 2022
Today, Lifecare 2021 annual report is published. 2021 was marked by several
important milestones:
o Regulatory approval for first-in-human pilot clinical trials
o Restructuring the organization - controlling development operations
o Reinforced Patent Protection and IP
o Successful Capital Increase
The report is subject to approval by the company's general meeting on 6 May
2022.
Lifecare AS' management team will host an online presentation of the 2021 annual
results today at 13:00 - 14:00 CET. The presentation will also include
development outlook and assumptions related to the patient and market potential
for Sencell. The report and the presentation are attached to this release and
are also available on Lifecare's website. The basis for the Sencell market
potential can be downloaded at
https://lifecare.no/publications/sencell-market-assumptions-and-commercial-poten
tial-april-2022/ There will be a Q&A session following the management
presentation.
The link to the webcast is available in the Investors section:
https://lifecare.no/events/webcast-annual-report-2021/. You can post questions
during the event or send them in advance to: kine.hereid@lifecare.no
Further information
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40
Today, Lifecare 2021 annual report is published. 2021 was marked by several
important milestones:
o Regulatory approval for first-in-human pilot clinical trials
o Restructuring the organization - controlling development operations
o Reinforced Patent Protection and IP
o Successful Capital Increase
The report is subject to approval by the company's general meeting on 6 May
2022.
Lifecare AS' management team will host an online presentation of the 2021 annual
results today at 13:00 - 14:00 CET. The presentation will also include
development outlook and assumptions related to the patient and market potential
for Sencell. The report and the presentation are attached to this release and
are also available on Lifecare's website. The basis for the Sencell market
potential can be downloaded at
https://lifecare.no/publications/sencell-market-assumptions-and-commercial-poten
tial-april-2022/ There will be a Q&A session following the management
presentation.
The link to the webcast is available in the Investors section:
https://lifecare.no/events/webcast-annual-report-2021/. You can post questions
during the event or send them in advance to: kine.hereid@lifecare.no
Further information
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40
Redigert 29.04.2022 kl 10:59
Du må logge inn for å svare
-
«
- 1
- 2 »
En tikkende bombe, neste nyhet kommer den å mange doble seg.
Da fikk jeg tatt en post i dag også:)
Betonghue
25.04.2022 kl 12:31
1670
Noe merkelig? Var du ikke fullastet allikevel? Arvet tante Olga? Snodig skrue du ....
Jeg har nå tatt et stort jafs aksjer:) Betonghue hva tenker du når nyheter kommer ut i verden om at 15 stk tester verdens ledende produkter inne diabetisk.
Holter holder på kortene, han sier innen Juni.
Holter holder på kortene, han sier innen Juni.
Nå som tvilere er ute på lave kurser, så kommer oppturen med Joacim Holter og resten av styre som sitter med millioner av aksjer her.
Husk de lastet for dager siden, for en grunn gjennombrudd et faktum. 2023-2031 himmelferd.
Husk de lastet for dager siden, for en grunn gjennombrudd et faktum. 2023-2031 himmelferd.
Go helg det blir spannede neste uke:) 06.05
Lifecare kommer snart på alle TV kanaler, om test av diabetikere med ny sensor og smart klokke.
Juni 2022 kommer nyheten.
Juni 2022 kommer nyheten.
Redigert 27.05.2022 kl 20:56
Du må logge inn for å svare
-
«
- 1
- 2 »